CFDE Data Portal | Search LINC02981

	Label	Description
	LINC02981 Gene (Entity type)	ENSG00000214870 - long intergenic non-protein coding RNA 2981
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 pirfenidone HL 5 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE193838 catechin 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC02981

ENSG00000214870 - long intergenic non-protein coding RNA 2981

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE150540 dipyridamole DPM HUVEC-C 1 v 2 human up

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 1 human up

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 5 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human up

A Gene Set from LINCS

GSE226249 pirfenidone HL 5 v 8 human up

A Gene Set from LINCS

GSE193838 catechin 0 v 2 human dn

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human dn

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 6 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.